Loading...

Pamela Munster, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone415-502-3598
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer
    NIH/NCI R01CA220131Jul 1, 2017 - May 31, 2022
    Role: Principal Investigator
    Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition
    NIH/NCI R01CA183071May 12, 2014 - Feb 28, 2019
    Role: Co-Principal Investigator
    The role of HDAC2 in hormone therapy resistance
    NIH/NCI R01CA152989Sep 19, 2011 - Jul 31, 2016
    Role: Principal Investigator
    The Role of Selective HDAC Enzymes in Drug Sensitivity
    NIH/NCI R01CA122657May 18, 2007 - Jul 31, 2012
    Role: Principal Investigator
    Potentiation of Topo Inhibitors by the HDACi, SAHA
    NIH/NCI R21CA112913Feb 6, 2006 - Jul 31, 2008
    Role: Principal Investigator
    Potentiation of Topo Inhibitors by HDAC Inhibitors
    NIH/NCI R21CA105875Sep 30, 2004 - May 31, 2007
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 May 18; 11(1):2543. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. PMID: 32424117.
      View in: PubMed   Mentions:    Fields:    
    2. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 Mar 19; 11(1):1459. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. PMID: 32193378.
      View in: PubMed   Mentions:    Fields:    
    3. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019; 11:10463-10476. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. PMID: 31853198.
      View in: PubMed   Mentions:
    4. Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials. JCO Oncol Pract. 2020 01; 16(1):e56-e63. Garrett SB, Matthews TM, Abramson CM, Koenig CJ, Hlubocky FJ, Daugherty CK, Munster PN, Dohan D. PMID: 31603726.
      View in: PubMed   Mentions:
    5. Reply: Strategies to Prevent Cardiotoxicity. J Am Coll Cardiol. 2019 10 01; 74(13):1737-1738. Guglin M, Tamura R, Krischer J, Munster PN. PMID: 31558261.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020 Feb 15; 26(4):804-811. Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. PMID: 31558480.
      View in: PubMed   Mentions:    Fields:    
    7. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One. 2019; 14(9):e0221994. Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. PMID: 31527867.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. Maintenance lenalidomide in primary CNS lymphoma. Ann Oncol. 2019 08 01; 30(8):1397-1398. Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B. PMID: 31046114.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology. 2019; 97(2):102-111. Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E. PMID: 31230047.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    10. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Jun 13. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. PMID: 31194228.
      View in: PubMed   Mentions: 9     Fields:    
    11. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019 06 11; 73(22):2859-2868. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN. PMID: 31171092.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Clin Cancer Res. 2019 08 15; 25(16):4917-4923. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C. PMID: 31152020.
      View in: PubMed   Mentions:    Fields:    
    13. A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. Pigment Cell Melanoma Res. 2019 07; 32(4):603-606. Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. PMID: 30801911.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. J Magn Reson. 2019 04; 301:73-79. Zhu Z, Zhu X, Ohliger MA, Tang S, Cao P, Carvajal L, Autry AW, Li Y, Kurhanewicz J, Chang S, Aggarwal R, Munster P, Xu D, Larson PEZ, Vigneron DB, Gordon JW. PMID: 30851668.
      View in: PubMed   Mentions:    Fields:    
    15. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018 10; 119(9):1086-1093. Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD. PMID: 30361524.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    16. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018 07 10; 2(13):1595-1607. Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B. PMID: 29986852.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    17. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 07 01; 29(7):1561-1568. Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P. PMID: 29726923.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    18. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clin Cancer Res. 2018 09 01; 24(17):4072-4080. Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, Le Tourneau C, O'Neil B, Mathijssen RHJ, Lopez-Martin JA, Edenfield WJ, Martin M, LoRusso PM, Bray GL, DiMartino J, Nguyen A, Liu K, Laille E, Bendell JC. PMID: 29764853.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    19. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018 07 01; 36(19):1981-1990. Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L. PMID: 29718793.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    20. Technique development of 3D dynamic CS-EPSI for hyperpolarized 13 C pyruvate MR molecular imaging of human prostate cancer. Magn Reson Med. 2018 11; 80(5):2062-2072. Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, Carvajal L, Cao P, Pauly JM, Kerr AB, Park I, Slater JB, Nelson SJ, Munster PN, Aggarwal R, Kurhanewicz J, Vigneron DB. PMID: 29575178.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    21. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 01 08; 8(1):92. Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN. PMID: 29311658.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    22. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017 Dec 26; 8(69):114156-114172. Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN. PMID: 29371976.
      View in: PubMed   Mentions: 6     Fields:    
    23. Host histone acetylation unlocks HDAC inhibitor potential. Oncotarget. 2017 Dec 05; 8(63):106161-106162. Terranova-Barberio M, Thomas S, Munster PN. PMID: 29290932.
      View in: PubMed   Mentions:    Fields:    
    24. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. PMID: 28893315.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    25. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer. Plast Reconstr Surg. 2017 Sep; 140(3):537-544. Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN. PMID: 28841614.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    26. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    27. What advanced cancer patients with limited treatment options know about clinical research: a qualitative study. Support Care Cancer. 2017 10; 25(10):3235-3242. Garrett SB, Koenig CJ, Trupin L, Hlubocky FJ, Daugherty CK, Reinert A, Munster P, Dohan D. PMID: 28488050.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 06 22; 129(25):3294-3303. Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R. PMID: 28483761.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    29. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 05 01; 28(5):1036-1041. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. PMID: 28453692.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    30. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. PMID: 28411193.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    31. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. Am Heart J. 2017 Jun; 188:87-92. Guglin M, Munster P, Fink A, Krischer J. PMID: 28577685.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    32. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4190-4202. Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS. PMID: 28298546.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    33. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer Manag Res. 2017; 9:65-72. Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ. PMID: 28293120.
      View in: PubMed   Mentions:
    34. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. PMID: 28221861.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    35. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360. Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. PMID: 27870570.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    36. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov; 78(5):921-927. Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. PMID: 27681579.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    37. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome. JAMA Oncol. 2016 08 01; 2(8):1089-90. Munster PN. PMID: 27228206.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Interest in initiating an early phase clinical trial: results of a longitudinal study of advanced cancer patients. Psychooncology. 2017 Oct; 26(10):1604-1610. Dunn LB, Wiley J, Garrett S, Hlubocky F, Daugherty C, Trupin L, Munster P, Dohan D. PMID: 27233054.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy. 2016 06; 8(6):705-19. Terranova-Barberio M, Thomas S, Munster PN. PMID: 27197539.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    40. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 05; 27(5):947-52. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. PMID: 26903311.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    41. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    42. Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients? Ann Oncol. 2016 Feb; 27(2):357. Rodriguez-Wallberg K, Turan V, Munster P, Oktay K. PMID: 26609009.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. PMID: 26603258.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    44. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. PMID: 26208485.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015 Sep; 51(14):1865-73. Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S. PMID: 26199039.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    46. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clin Cancer Res. 2015 Dec 01; 21(23):5235-44. Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA. PMID: 26187616.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    47. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 01; 121(19):3481-90. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. PMID: 26177599.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    48. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    49. More Options for Fertility Preservation for Patients With Cancer. J Clin Oncol. 2015 Aug 01; 33(22):2413-5. Munster PN. PMID: 26101241.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015 06 04; 372(23):2268-9. Oktay K, Rodriguez-Wallberg K, Munster P. PMID: 26039611.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    51. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015 Feb 25; 17:26. Raha P, Thomas S, Thurn KT, Park J, Munster PN. PMID: 25848915.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    52. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. PMID: 25605849.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsCTClinical Trials
    53. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015; 7(4):641-52. Park J, Thomas S, Munster PN. PMID: 26111034.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    54. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug; 74(2):359-65. Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. PMID: 24934865.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    55. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother. 2014 Jun; 15(9):1277-88. Zhang X, Munster PN. PMID: 24787047.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    56. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. PMID: 24711549.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    57. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar; 73(3):467-73. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R. PMID: 24390424.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    58. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41. Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL. PMID: 24190981.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    59. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemother Pharmacol. 2014 Jan; 73(1):103-11. Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A. PMID: 24178368.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    60. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med. 2013 Aug 14; 5(198):198ra108. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. PMID: 23946197.
      View in: PubMed   Mentions: 303     Fields:    Translation:Humans
    61. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 2013 Oct; 12(10):2078-87. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. PMID: 23939379.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    62. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One. 2013; 8(7):e68973. Thomas S, Thurn KT, Raha P, Chen S, Munster PN. PMID: 23874830.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    63. Fertility preservation and breast cancer: A complex problem. Oncology (Williston Park). 2013 Jun; 27(6):533-9. Munster PN. PMID: 23909066.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    64. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013 Jun 10; 31(17):2128-35. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. PMID: 23650416.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    65. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    66. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. PMID: 23470967.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    67. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. PMID: 23197589.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    68. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. PMID: 22798157.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    69. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012 Jun; 133(3):1057-65. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. PMID: 22418700.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    70. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Feb 10; 30(5):533-8. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. PMID: 22231041.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    71. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012 Jan 03; 106(1):85-91. Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. PMID: 22127285.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    72. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs. 2011 Nov; 20(11):1565-74. Munster PN, Daud AI. PMID: 21985236.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    73. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 2011 Aug; 3(4):451-70. Raha P, Thomas S, Munster PN. PMID: 22126205.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    74. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol. 2012 Mar; 23(3):610-7. Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E, Fumoleau P, Ward R, Bardy-Bouxin N, Leip E, Turnbull K, Zacharchuk C, Epstein RJ. PMID: 21700731.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    75. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 07; 104(12):1828-35. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. PMID: 21559012.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCellsCTClinical Trials
    76. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet. 2011 May 15; 157C(2):136-46. Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH. PMID: 21495172.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    77. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011 Feb; 7(2):263-83. Thurn KT, Thomas S, Moore A, Munster PN. PMID: 21345145.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCells
    78. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7077-84. Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M. PMID: 19887475.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    79. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009 Oct 06; 101(7):1044-50. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. PMID: 19738609.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsCTClinical Trials
    80. Estradiol in breast cancer treatment: reviving the past. JAMA. 2009 Aug 19; 302(7):797-8. Munster PN, Carpenter JT. PMID: 19690316.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    81. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009 Jun; 19(3):167-75. Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. PMID: 19434004.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    82. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009 Apr 15; 115(8):1776-83. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. PMID: 19224550.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    83. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res. 2009 Apr 15; 15(8):2942-8. Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM. PMID: 19351752.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    84. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther. 2009 Apr; 8(4):794-801. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. PMID: 19372552.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    85. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009 Apr 01; 15(7):2552-8. Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA. PMID: 19318484.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    86. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 Apr 01; 15(7):2488-96. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. PMID: 19318486.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCellsCTClinical Trials
    87. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr 01; 15(7):2479-87. Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. PMID: 19318485.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    88. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett. 2009 Aug 08; 280(2):184-91. Thomas S, Munster PN. PMID: 19185986.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    89. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec 20; 26(36):5896-903. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. PMID: 19029422.
      View in: PubMed   Mentions: 172     Fields:    Translation:HumansCTClinical Trials
    90. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 2008 Nov 15; 113(10):2646-54. Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D. PMID: 18823053.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    91. Activated stat-3 in melanoma. Cancer Control. 2008 Jul; 15(3):196-201. Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. PMID: 18596671.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    92. Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory. J Pain Symptom Manage. 2008 Nov; 36(5):480-7. Donovan KA, Jacobsen PB, Small BJ, Munster PN, Andrykowski MA. PMID: 18495413.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    93. Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach. Support Care Cancer. 2008 Aug; 16(8):925-33. Gwede CK, Small BJ, Munster PN, Andrykowski MA, Jacobsen PB. PMID: 18043948.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    94. Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer. 2007 Oct 15; 110(8):1851-9. Jacobsen PB, Donovan KA, Small BJ, Jim HS, Munster PN, Andrykowski MA. PMID: 17847016.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    95. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct 01; 13(19):5855-61. Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. PMID: 17908979.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    96. Physical symptoms/side effects during breast cancer treatment predict posttreatment distress. Ann Behav Med. 2007 Oct; 34(2):200-8. Jim HS, Andrykowski MA, Munster PN, Jacobsen PB. PMID: 17927558.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    97. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemother Pharmacol. 2008 Jun; 62(1):97-109. Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A. PMID: 17805538.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    98. Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment. Health Psychol. 2007 Jul; 26(4):464-72. Donovan KA, Small BJ, Andrykowski MA, Munster P, Jacobsen PB. PMID: 17605566.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    99. Discussion of fertility preservation with newly diagnosed patients: oncologists' views. J Cancer Surviv. 2007 Jun; 1(2):146-55. Quinn GP, Vadaparampil ST, Gwede CK, Miree C, King LM, Clayton HB, Wilson C, Munster P. PMID: 18648955.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    100. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 2007 Feb 15; 13(4):1238-45. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. PMID: 17317835.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    101. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec 01; 108(12):3881-9. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. PMID: 16917002.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCellsCTClinical Trials
    102. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 01; 12(15):4645-51. Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. PMID: 16899614.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    103. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug; 5(8):2130-7. Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN. PMID: 16928835.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    104. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006 Jul; 13(3):211-7. Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. PMID: 16885917.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    105. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol. 2006 Jul 01; 24(19):3013-8. Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. PMID: 16769985.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    106. Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opin Investig Drugs. 2006 Mar; 15(3):317-26. Munster PN. PMID: 16503767.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    107. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005 Dec; 4(12):1993-2000. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. PMID: 16373714.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    108. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005 Dec 01; 11(23):8467-75. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. PMID: 16322310.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    109. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005 Dec 01; 104(11):2499-507. Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. PMID: 16247788.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    110. Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model. DNA Cell Biol. 2005 Jul; 24(7):470-5. Xu Q, Brabham JG, Zhang S, Munster P, Fields K, Zhao RJ, Yu H. PMID: 16008516.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    111. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 May 01; 65(9):3815-22. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. PMID: 15867379.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    112. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res. 2005 Apr 15; 11(8):3009-16. Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. PMID: 15837755.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    113. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May 15; 92(2):223-37. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. PMID: 15108350.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    114. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. PMID: 12637464.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    115. Improving breast cancer care. Cancer Control. 2002 Nov-Dec; 9(6):455-6. Munster PN. PMID: 12514562.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    116. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002 Nov-Dec; 9(6):466-72. Minton SE, Munster PN. PMID: 12514564.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    117. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002 Feb 14; 21(8):1159-66. Basso AD, Solit DB, Munster PN, Rosen N. PMID: 11850835.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    118. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001 Dec 01; 61(23):8492-7. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. PMID: 11731433.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCells
    119. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001. Cancer Control. 2001 Nov-Dec; 8(6):478-9. Munster PN, Horton J. PMID: 11807416.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    120. Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res. 2001; 3(6):361-4. Munster PN, Norton L. PMID: 11737886.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    121. New drugs in gynecologic cancer. Curr Treat Options Oncol. 2001 Apr; 2(2):119-28. Daud A, Munster P, Munster P, Spriggs DR. PMID: 12057130.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    122. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol. 2001 Mar; 8(3):289-99. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. PMID: 11306353.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    123. Update on the management of advanced breast cancer. Oncology (Williston Park). 1999 May; 13(5):647-58; discussion 660, 663-4. Fornier M, Munster P, Seidman AD. PMID: 10356685.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans